Friday 6-20-2014 Cytrx Corp (CYTR) $CYTR opened at 5.00 hitting the high price of 5.00 and a day low of 4.66 with a total volume of 2,093,050. CYTR had a previous close of 4.96 and has been seeing an average volume of 1,905,270.
Overall Average: 40% Buy
Recent stock forum discussions about CYTR http://investorshangout.com/search?q=CYTR&...mp;yt0=Go!
CytRx Has Returned 26.2% Since SmarTrend Recommendation (CYTR)
Comtex SmarTrend(R) - Thu Jun 19, 9:14AM CDT
SmarTrend identified an Uptrend for CytRx (NASDAQ:CYTR) on May 27th, 2014 at $3.99. In approximately 3 weeks, CytRx has returned 26.22% as of today's recent price of $5.03. (full story)
5 Stocks Poised for Breakouts
at The Street - Fri Jun 13, 12:22PM CDT
These stocks look ready to break out and trade higher from current levels. (full story)
Technical Update, Leadership Appointments, and Clinical Trial Results - Analyst Notes on Achillion, Nektar, CytRx, Galena and Receptos
PR Newswire - Thu Jun 12, 4:20AM CDT
Today, Analysts Review released its analysts' notes regarding Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN), Nektar Therapeutics (NASDAQ: NKTR), CytRx Corporation (NASDAQ: CYTR), Galena Biopharma, Inc. (NASDAQ: GALE) and Receptos, Inc. (NASDAQ: RCPT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3633-100free. (full story)
CytRx Shares Up 26.0% Since SmarTrend's Buy Recommendation (CYTR)
Comtex SmarTrend(R) - Wed Jun 11, 5:06PM CDT
SmarTrend identified an Uptrend for CytRx (NASDAQ:CYTR) on May 27th, 2014 at $3.99. In approximately 2 weeks, CytRx has returned 25.97% as of today's recent price of $5.02. (full story)
Hot Stock: CytRx, Shares Gain 9.1% (CYTR)
Comtex SmarTrend(R) - Mon Jun 09, 10:40AM CDT
CytRx (NASDAQ:CYTR) is one of today's best performing low-priced stocks, up 9.1% to $4.78 on 1.1x average daily volume. Thus far today, CytRx has traded 1.5 million shares, vs. average volume of 1.4 million shares per day. The stock has outperformed the Dow (9.1% to the Dow's 0.2%) and outperformed the S&P 500 (9.1% to the S&P's 0.2%) during today's trading. (full story)
5 Stocks Poised to Break Out
at The Street - Fri Jun 06, 1:27PM CDT
These stocks look ready to break out and trade higher from current levels. (full story)
3 Stocks Under $10 Moving Higher
at The Street - Wed Jun 04, 8:18AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits. (full story)
5 Stocks Under $10 Set to Soar
at The Street - Thu May 29, 12:54PM CDT
These under-$10 stocks are within range of triggering breakout trades. (full story)
CytRx to Present at the Jefferies 2014 Global Healthcare Conference
Business Wire - Thu May 29, 5:00AM CDT
CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that President and CEO Steven A. Kriegsman and Vice President of Business Development David Haen will present at the Jefferies 2014 Global Healthcare Conference on Wednesday, June 4, 2014 at 9:30 a.m. Eastern Time. The conference is being held June 2-5 in New York City. (full story)
Wednesday’s Top Health Care Stories: Valeant, Allergan, GlaxoSmithKline, and CytRx
Leo Sun, The Motley Fool - Motley Fool - Wed May 28, 8:24AM CDT
Let's take a closer look at four stocks -- Valeant Pharmaceuticals , Allergan , GlaxoSmithKline , and CytRx -- which could all loom large in Wednesday's health care headlines. Valeant... (full story)
CytRx Highlights Aldoxorubicin Data from its Global Phase 2b Clinical Trial in First-Line Soft Tissue Sarcoma
Business Wire - Wed May 28, 5:00AM CDT
--Aldoxorubicin Demonstrated Highly Statistically Significant Increases in PFS, PFS at 6 Months and ORR, Compared to Doxorubicin (full story)
3 Biotech Stocks Under $10 to Watch
at The Street - Wed May 14, 5:00AM CDT
Keep an eye on these under-$10 biotech stocks. (full story)
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against CytRx Corporation and Certain Officers - CYTR
PR Newswire - Fri May 09, 5:15PM CDT
Pomerantz LLP announces the filing of a class action lawsuit against CytRx Corporation ("CytRx" or the "Company"
(NASDAQ: CYTR) and certain of its officers. The class action, filed in United States District Court, Central District of California and docketed under 14-cv-02689, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired securities of CytRX between November 22, 2013 and March 13, 2014, both dates inclusive (the "Class Period" . This class action seeks to recover damages against the Company and certain of its officers and directors as a result of alleged violations of the federal securities laws pursuant to Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder. (full story)
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in CytRx Corporation to Contact Brower Piven Before the May 13, 2014 Lead Plaintiff Deadline -- CYTR
GlobeNewswire - Thu May 08, 10:45AM CDT
Brower Piven, A Professional Corporation announces that a class action lawsuit has been commenced in the United States District Court for the Central District of California on behalf of purchasers of CytRx Corporation ("CytRx" or the "Company" (Nasdaq:CYTR) common stock during the period between November 22, 2013 and March 13, 2014, inclusive (the "Class Period" . (full story)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against CYTRX CORPORATION and Its Board of Directors and a Lead Plaintiff Deadline of May 13, 2014 -- CYTR
GlobeNewswire - Tue May 06, 12:02PM CDT
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Central District of California on behalf of investors who purchased CytRx Corporation ("CytRx" or the "Company" (Nasdaq:CYTR) common stock between November 22, 2013 and March 13, 2014. (full story)
Hagens Berman: 7 Days Remain Until May 13, 2014 Lead Plaintiff Deadline in CytRx Securities Fraud Class Action
PR Newswire - Tue May 06, 11:26AM CDT
Hagens Berman Sobol Shapiro LLP reminds investors of the securities fraud class action against CytRx Corporation (NASDAQ: CYTR) ("CytRx" or "the Company" and the May 13, 2014 deadline to file for lead plaintiff. Investors who have suffered financial losses can contact Hagens Berman Partner Reed Kathrein, who is leading the firm's investigation, by emailing CytRx@hbsslaw.com, calling 510-725-3000 or visiting http://hb-securities.com/investigations/CytRx. (full story)
INVESTOR ALERT: Glancy Binkow & Goldberg LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Lawsuit Against CytRx Corporation
Business Wire - Tue May 06, 9:32AM CDT
Glancy Binkow & Goldberg LLP reminds investors of CytRx Corporation ("CytRx" or the "Company" (NASDAQ:CYTR) that all purchasers of CytRx securities between November 20, 2013 and March 13, 2014, inclusive (the "Class Period" , have until May 13, 2014, to file a motion to be appointed as lead plaintiff in the shareholder lawsuit. (full story)
CytRx Reports Completed Phase 1b/2 Progression-Free Survival and Overall Survival Aldoxorubicin Data in Second-Line Soft Tissue Sarcoma
Business Wire - Mon May 05, 5:00AM CDT
--Median Overall Survival Data Support the Ongoing Clinical Development of Aldoxorubicin in Soft Tissue Sarcoma (full story)
Overall Average: 40% Buy
Recent stock forum discussions about CYTR http://investorshangout.com/search?q=CYTR&...mp;yt0=Go!
CytRx Has Returned 26.2% Since SmarTrend Recommendation (CYTR)
Comtex SmarTrend(R) - Thu Jun 19, 9:14AM CDT
SmarTrend identified an Uptrend for CytRx (NASDAQ:CYTR) on May 27th, 2014 at $3.99. In approximately 3 weeks, CytRx has returned 26.22% as of today's recent price of $5.03. (full story)
5 Stocks Poised for Breakouts
at The Street - Fri Jun 13, 12:22PM CDT
These stocks look ready to break out and trade higher from current levels. (full story)
Technical Update, Leadership Appointments, and Clinical Trial Results - Analyst Notes on Achillion, Nektar, CytRx, Galena and Receptos
PR Newswire - Thu Jun 12, 4:20AM CDT
Today, Analysts Review released its analysts' notes regarding Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN), Nektar Therapeutics (NASDAQ: NKTR), CytRx Corporation (NASDAQ: CYTR), Galena Biopharma, Inc. (NASDAQ: GALE) and Receptos, Inc. (NASDAQ: RCPT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3633-100free. (full story)
CytRx Shares Up 26.0% Since SmarTrend's Buy Recommendation (CYTR)
Comtex SmarTrend(R) - Wed Jun 11, 5:06PM CDT
SmarTrend identified an Uptrend for CytRx (NASDAQ:CYTR) on May 27th, 2014 at $3.99. In approximately 2 weeks, CytRx has returned 25.97% as of today's recent price of $5.02. (full story)
Hot Stock: CytRx, Shares Gain 9.1% (CYTR)
Comtex SmarTrend(R) - Mon Jun 09, 10:40AM CDT
CytRx (NASDAQ:CYTR) is one of today's best performing low-priced stocks, up 9.1% to $4.78 on 1.1x average daily volume. Thus far today, CytRx has traded 1.5 million shares, vs. average volume of 1.4 million shares per day. The stock has outperformed the Dow (9.1% to the Dow's 0.2%) and outperformed the S&P 500 (9.1% to the S&P's 0.2%) during today's trading. (full story)
5 Stocks Poised to Break Out
at The Street - Fri Jun 06, 1:27PM CDT
These stocks look ready to break out and trade higher from current levels. (full story)
3 Stocks Under $10 Moving Higher
at The Street - Wed Jun 04, 8:18AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits. (full story)
5 Stocks Under $10 Set to Soar
at The Street - Thu May 29, 12:54PM CDT
These under-$10 stocks are within range of triggering breakout trades. (full story)
CytRx to Present at the Jefferies 2014 Global Healthcare Conference
Business Wire - Thu May 29, 5:00AM CDT
CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that President and CEO Steven A. Kriegsman and Vice President of Business Development David Haen will present at the Jefferies 2014 Global Healthcare Conference on Wednesday, June 4, 2014 at 9:30 a.m. Eastern Time. The conference is being held June 2-5 in New York City. (full story)
Wednesday’s Top Health Care Stories: Valeant, Allergan, GlaxoSmithKline, and CytRx
Leo Sun, The Motley Fool - Motley Fool - Wed May 28, 8:24AM CDT
Let's take a closer look at four stocks -- Valeant Pharmaceuticals , Allergan , GlaxoSmithKline , and CytRx -- which could all loom large in Wednesday's health care headlines. Valeant... (full story)
CytRx Highlights Aldoxorubicin Data from its Global Phase 2b Clinical Trial in First-Line Soft Tissue Sarcoma
Business Wire - Wed May 28, 5:00AM CDT
--Aldoxorubicin Demonstrated Highly Statistically Significant Increases in PFS, PFS at 6 Months and ORR, Compared to Doxorubicin (full story)
3 Biotech Stocks Under $10 to Watch
at The Street - Wed May 14, 5:00AM CDT
Keep an eye on these under-$10 biotech stocks. (full story)
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against CytRx Corporation and Certain Officers - CYTR
PR Newswire - Fri May 09, 5:15PM CDT
Pomerantz LLP announces the filing of a class action lawsuit against CytRx Corporation ("CytRx" or the "Company"
(NASDAQ: CYTR) and certain of its officers. The class action, filed in United States District Court, Central District of California and docketed under 14-cv-02689, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired securities of CytRX between November 22, 2013 and March 13, 2014, both dates inclusive (the "Class Period" . This class action seeks to recover damages against the Company and certain of its officers and directors as a result of alleged violations of the federal securities laws pursuant to Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder. (full story) SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in CytRx Corporation to Contact Brower Piven Before the May 13, 2014 Lead Plaintiff Deadline -- CYTR
GlobeNewswire - Thu May 08, 10:45AM CDT
Brower Piven, A Professional Corporation announces that a class action lawsuit has been commenced in the United States District Court for the Central District of California on behalf of purchasers of CytRx Corporation ("CytRx" or the "Company"
(Nasdaq:CYTR) common stock during the period between November 22, 2013 and March 13, 2014, inclusive (the "Class Period" . (full story) SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against CYTRX CORPORATION and Its Board of Directors and a Lead Plaintiff Deadline of May 13, 2014 -- CYTR
GlobeNewswire - Tue May 06, 12:02PM CDT
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Central District of California on behalf of investors who purchased CytRx Corporation ("CytRx" or the "Company"
(Nasdaq:CYTR) common stock between November 22, 2013 and March 13, 2014. (full story) Hagens Berman: 7 Days Remain Until May 13, 2014 Lead Plaintiff Deadline in CytRx Securities Fraud Class Action
PR Newswire - Tue May 06, 11:26AM CDT
Hagens Berman Sobol Shapiro LLP reminds investors of the securities fraud class action against CytRx Corporation (NASDAQ: CYTR) ("CytRx" or "the Company"
and the May 13, 2014 deadline to file for lead plaintiff. Investors who have suffered financial losses can contact Hagens Berman Partner Reed Kathrein, who is leading the firm's investigation, by emailing CytRx@hbsslaw.com, calling 510-725-3000 or visiting http://hb-securities.com/investigations/CytRx. (full story) INVESTOR ALERT: Glancy Binkow & Goldberg LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Lawsuit Against CytRx Corporation
Business Wire - Tue May 06, 9:32AM CDT
Glancy Binkow & Goldberg LLP reminds investors of CytRx Corporation ("CytRx" or the "Company"
(NASDAQ:CYTR) that all purchasers of CytRx securities between November 20, 2013 and March 13, 2014, inclusive (the "Class Period" , have until May 13, 2014, to file a motion to be appointed as lead plaintiff in the shareholder lawsuit. (full story) CytRx Reports Completed Phase 1b/2 Progression-Free Survival and Overall Survival Aldoxorubicin Data in Second-Line Soft Tissue Sarcoma
Business Wire - Mon May 05, 5:00AM CDT
--Median Overall Survival Data Support the Ongoing Clinical Development of Aldoxorubicin in Soft Tissue Sarcoma (full story)
